Paola Ghione
Paola Ghione is an expert in Hematology at Memorial Sloan Kettering Cancer Center (United States). As of September 2026, ScienceLeadR ranks Paola Ghione in the top 1% of experts worldwide for Lymphoma. Paola Ghione has authored 177 publications, the most recent in 2026, and is an investigator in 9 clinical trials, 1 of them ongoing. SLR score: 668 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2010 - 2026
Number : 177
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma. PMID 42431614 — cells, lymphoma, b-cell, lymphoma, mutation, b-lymphocytes, prognosis | Blood Adv | 2026 | 0 |
| Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs. PMID 42379251 — cells, bone marrow, blood, neutropenia, duration of therapy, retreatment, therapeutics, t-lymphocytes, infections | Blood Adv | 2026 | 0 |
| Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns. PMID 42273944 — cells, hematology, lymphoma, drug therapy, histology, therapeutics, lymphoma, t-cell, peripheral, t-lymphocytes, lymphoma, t-cell, chemotherapy | Haematologica | 2026 | 0 |
| High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis. PMID 42274647 — cells, lymphoma, b-cell, lymphoma, b-lymphocytes, methotrexate | J Clin Oncol Top journal | 2026 | 0 |
| Non-JAK-family gene fusions in cutaneous T-cell lymphoma highlights genetic diversity and potential therapeutic targets. PMID 41852317 — cells, genetic variation, genes, hematology, lymphoma, gene fusion, lymphoma, t-cell, cutaneous, therapeutics, t-lymphocytes, lymphoma, t-cell | Haematologica | 2026 | 0 |
Clinical Studies 9
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Epco Zanu Ritux for R R FL or MZL NCT06563596 — injections, skin, cells, lymphoma, follicular, hodgkin disease, lymphoma, b-cell, lymphoma, lymphoma, b-cell, marginal zone, capsules, rituximab, protein-tyrosine kinases, antibodies, monoclonal, lymphoma, non-hodgkin, agammaglobulinaemia tyrosine kinase, tyrosine, therapeutics, infusions, intravenous, b-lymphocytes, epcoritamab | Phase 2 | Recruiting | 2025 |
LeadR Networks
Main global connection map